
From the discovery and development of biopharmaceuticals to the design of medical devices, Canada's life sciences sectors offer foreign investors world-class R&D infrastructure, leading healthcare specialists and a regulatory environment that rewards innovation. Canada's bio-based economy totals \$78.3 billion in sales and leads the G7 in the growth of health research patents.

Canada's robust life sciences industry is pulsing with talent, creativity and achievement. This sector has biopharmaceutical and medical device firms commercializing groundbreaking products, with the support of a top-notch research community of over 100 institutes, 670 biotech companies and over 28,000 employees. With groundbreaking innovations and a safe, efficient regulatory system in place, the industry is injected with a healthy dose of success.

Biopharmaceuticals

Canadian cities have some of the lowest cost metrics in biotechnology R&D in North America



BIOTECH R&D OPERATING-COST COMPARISONS IN NORTH AMERICA Source: IBM Plant Location International. 2009.

Loewendahl, H. Future Challenges of Investment Promotion. fDi Intelligence. September 23, 2009. p. 42. ONE OF THE MOST INNOVATIVE and profitable sectors in the country, Canada's domestic pharmaceutical industry is a \$20-billion market—the world's ninthlargest. Among our peer G7 nations, Canada's biopharmaceuticals industry is the fastest-growing and benefits from the lowest biotech labour costs. The sector is largely clustered in Montréal, Toronto and Vancouver—all of which fall in the Top 10 cities in North America for life science patents.¹ Canada also leads the G7 nations in the growth of health research patents.

Such high levels of innovation are reflective of the \$1.3 billion spent annually on biopharmaceutical R&D and the \$600 million on clinical trials across the country. Canada also frequently leads the world in approving groundbreaking drugs and therapies. Canadian biotech and pharmaceutical firms have over 300 products under development or on the market. Indeed, our biopharmaceutical prowess has captured the attention and confidence of the world's pharmaceutical giants.

Vaccines

In 2007, **GSK Biologicals**, a division of U.K. multinational **GlaxoSmithKline** (**GSK**), invested nearly \$200 million in upgrading and expanding its vaccine production facility in Québec City. It also invested \$50 million in its vaccine R&D headquarters in Laval, Quebec—making Laval its North American centre for vaccine R&D. GSK Biologicals is one of only two manufacturers of influenza vaccine on the continent.